{"entity":{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","aka":["PACIFIC-5"],"tldr":"A phase 3 trial of Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03706690 by AstraZeneca, with 407 participants enrolled, started 2018-11-27 and due to reach its primary completion in 2024-06-23. Interventions recorded: Durvalumab. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03706690","url":"https://clinicaltrials.gov/study/NCT03706690"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","stage-iii-unresectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03706690-j-hematol-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03706690","phase":"3","setting":"A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy","sponsor":"AstraZeneca","started":"2018-11-27","startedType":"actual","yearReported":2025,"enrolled":407,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)","primary":true,"unit":"months","arms":[{"name":"Durvalumab","n":252,"value":14,"note":"95% CI 10.9 to 18.0; Figures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication"},{"name":"Placebo","n":129,"value":6.5,"note":"95% CI 5.4 to 13.8"}],"hr":0.75,"ci":[0.578,0.986],"p":"0.038","source":"https://clinicaltrials.gov/study/NCT03706690?tab=results"},{"endpoint":"Overall Survival (OS), ITT set","unit":"months","arms":[{"name":"Durvalumab","n":272,"value":38.4,"note":"95% CI 29.0 to 42.9; Figures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication"},{"name":"Placebo","n":135,"value":32.5,"note":"95% CI 20.6 to 40.4"}],"hr":0.87,"ci":[0.656,1.166],"p":"0.346","source":"https://clinicaltrials.gov/study/NCT03706690?tab=results"},{"endpoint":"Objective Response Rate (ORR), ITT set","unit":"%","arms":[{"name":"Durvalumab","n":240,"value":27.1,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication"},{"name":"Placebo","n":127,"value":19.7}],"p":"0.128","source":"https://clinicaltrials.gov/study/NCT03706690?tab=results"}]},"route":"/trials/nct03706690/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/"}]}}